ライフサイエンスコーパス: melanoma-specific survival

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ant disease control and resulted in enhanced melanoma-specific survival.

2 The primary end point was melanoma-specific survival.

3 Recurrence, overall survival, and melanoma-specific survival.

4 s of this analysis were overall survival and melanoma-specific survival.

5 dissection was not associated with increased melanoma-specific survival among 1934 patients with data

6 prognostic information but did not increase melanoma-specific survival among patients with melanoma

7 ults from prior studies.OBJECTIVE To compare melanoma-specific survival between patients with histopa

8 The 5-year melanoma specific survival calculated from the date of t

9 Melanoma-specific survival estimates to December 31, 200

10 to extend disease free survival and increase melanoma-specific survival for patients with early nodal

11 d prolongs distant disease-free survival and melanoma-specific survival for patients with nodal metas

12 mitotic rate was a significant predictor of melanoma-specific survival (Hazard Ratio [HR] = 1.2, 95%

13 tus was an independent prognostic factor for melanoma-specific survival (hazard ratio [HR] = 1.34; 95

14 tasis, 0.62; P=0.02) and the 10-year rate of melanoma-specific survival (hazard ratio for death from

15 mph-node biopsy is associated with increased melanoma-specific survival (i.e., survival until death f

16 whereas a marker in EBF1 was associated with melanoma-specific survival in advanced-stage patients (r

17 (P<0.0001) and significantly associated with melanoma-specific survival in both stage III (P<0.0001)

18 all six genes were significant in predicting melanoma specific survival (MSS) in a univariate analysi

19 Conditional melanoma-specific survival (MSS) estimates up to 5 years

20 The 5-year melanoma-specific survival (MSS) for ulcerated and nonul

21 Melanoma-specific survival (MSS) was not significantly d

22 d rates of 10-year overall survival (OS) and melanoma-specific survival (MSS) were 82% and 94%, respe

23 status, recurrence-free survival (RFS), and melanoma-specific survival (MSS) were analyzed.

24 Disease-free survival, melanoma-specific survival (MSS), and overall survival.

25 l lymph node (SLN) had significantly reduced melanoma-specific survival (MSS), DFS, regional node rec

26 G) of these loci had markedly reduced OS and melanoma-specific survival (MSS).

27 nce of CTC status for disease recurrence and melanoma-specific survival (MSS).

28 sociated with poorer overall (OS; P < .001), melanoma-specific survival (MSS; P = .0025), and disease

29 Children with melanoma had a 5-year melanoma-specific survival of 93.6% (95% CI, 91.9 to 94.

30 Clinicopathologic predictors and melanoma-specific survival of histologically amelanotic

31 in the recurrence rate, overall survival, or melanoma-specific survival of patients with MIS treated

32 Tumor characteristics and melanoma-specific survival of primary melanoma by NRAS a

33 The 5-year uveal melanoma-specific survival probability was 82.9% (95% CI

34 ntermediate-thickness melanomas, the 10-year melanoma-specific survival rate was 62.1 +/- 4.8% among

35 treatment-related difference in the 10-year melanoma-specific survival rate was seen in the overall

36 1), distant-metastasis-free (P = 0.029), and melanoma-specific survival rates (P = 0.029) in CM.

37 Factors predicting melanoma-specific survival rates were analyzed using the

38 Melanoma-specific survival rates were not different betw

39 Five-year melanoma-specific survival rates were similar in the two

40 , ulceration) yields a wide range of 10-year melanoma-specific survival rates.

41 There was no significant difference in melanoma-specific survival (reported as hazard ratios [9

42 sults suggest that the MAPK pathway mediates melanoma-specific survival signaling by differentially r

43 However, melanoma-specific survival was significantly poorer for

44 Melanoma-specific survival was significantly worse for p

45 ol analysis, the mean (+/-SE) 3-year rate of melanoma-specific survival was similar in the dissection

46 or characteristics, disease progression, and melanoma-specific survival were recorded.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。